Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic miRNAs Between Extracellular Vesicles, HDL and Ago-2.

Florijn BW, Duijs JMGJ, Levels JH, Dallinga-Thie GM, Wang Y, Boing AN, Yuana Y, Stam W, Limpens RWAL, Au YW, Nieuwland R, Rabelink TJ, Reinders MEJ, Jan van Zonneveld A, Bijkerk R.

Diabetes. 2019 Sep 10. pii: db181360. doi: 10.2337/db18-1360. [Epub ahead of print]

PMID:
31506344
2.

Long Non-coding RNAs Rian and Miat Mediate Myofibroblast Formation in Kidney Fibrosis.

Bijkerk R, Au YW, Stam W, Duijs JMGJ, Koudijs A, Lievers E, Rabelink TJ, van Zonneveld AJ.

Front Pharmacol. 2019 Mar 11;10:215. doi: 10.3389/fphar.2019.00215. eCollection 2019.

3.

Neutral endopeptidase inhibitors blunt kidney fibrosis by reducing myofibroblast formation.

Bijkerk R, Aleksinskaya MA, Duijs JMGJ, Veth J, Husen B, Reiche D, Prehn C, Adamski J, Rabelink TJ, De Mey JGR, van Zonneveld AJ.

Clin Sci (Lond). 2019 Jan 22;133(2):239-252. doi: 10.1042/CS20180882. Print 2019 Jan 31.

PMID:
30617188
4.

Vascular Calcification and not Arrhythmia in Idiopathic Atrial Fibrillation Associates with Sex Differences in Diabetic Microvascular Injury miRNA Profiles.

Dudink E, Florijn B, Weijs B, Duijs J, Luermans J, Peeters F, Schurgers L, Wildberger J, Schotten U, Bijkerk R, Crijns HJ, van Zonneveld AJ.

Microrna. 2019;8(2):127-134. doi: 10.2174/2211536608666181122125208.

PMID:
30465521
5.

Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury.

Bijkerk R, Florijn BW, Khairoun M, Duijs JMGJ, Ocak G, de Vries APJ, Schaapherder AF, Mallat MJK, de Fijter JW, Rabelink TJ, van Zonneveld AJ, Reinders MEJ.

Transplant Direct. 2017 Jun 19;3(7):e174. doi: 10.1097/TXD.0000000000000699. eCollection 2017 Jul.

6.

Promoting Tropoelastin Expression in Arterial and Venous Vascular Smooth Muscle Cells and Fibroblasts for Vascular Tissue Engineering.

Rothuizen TC, Kemp R, Duijs JM, de Boer HC, Bijkerk R, van der Veer EP, Moroni L, van Zonneveld AJ, Weiss AS, Rabelink TJ, Rotmans JI.

Tissue Eng Part C Methods. 2016 Oct;22(10):923-931. doi: 10.1089/ten.TEC.2016.0173. Epub 2016 Sep 28.

PMID:
27604583
7.

Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation.

Bijkerk R, de Bruin RG, van Solingen C, van Gils JM, Duijs JM, van der Veer EP, Rabelink TJ, Humphreys BD, van Zonneveld AJ.

Kidney Int. 2016 Jun;89(6):1268-80. doi: 10.1016/j.kint.2016.01.029. Epub 2016 Apr 8.

PMID:
27165825
8.

Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression.

de Bruin RG, Shiue L, Prins J, de Boer HC, Singh A, Fagg WS, van Gils JM, Duijs JM, Katzman S, Kraaijeveld AO, Böhringer S, Leung WY, Kielbasa SM, Donahue JP, van der Zande PH, Sijbom R, van Alem CM, Bot I, van Kooten C, Jukema JW, Van Esch H, Rabelink TJ, Kazan H, Biessen EA, Ares M Jr, van Zonneveld AJ, van der Veer EP.

Nat Commun. 2016 Mar 31;7:10846. doi: 10.1038/ncomms10846.

9.

Development and evaluation of in vivo tissue engineered blood vessels in a porcine model.

Rothuizen TC, Damanik FFR, Lavrijsen T, Visser MJT, Hamming JF, Lalai RA, Duijs JMGJ, van Zonneveld AJ, Hoefer IE, van Blitterswijk CA, Rabelink TJ, Moroni L, Rotmans JI.

Biomaterials. 2016 Jan;75:82-90. doi: 10.1016/j.biomaterials.2015.10.023. Epub 2015 Oct 22.

PMID:
26491997
10.

Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation.

Bijkerk R, Duijs JM, Khairoun M, Ter Horst CJ, van der Pol P, Mallat MJ, Rotmans JI, de Vries AP, de Koning EJ, de Fijter JW, Rabelink TJ, van Zonneveld AJ, Reinders ME.

Am J Transplant. 2015 Apr;15(4):1081-90. doi: 10.1111/ajt.13072. Epub 2015 Feb 25.

11.

Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy.

Reinders ME, Roemeling-van Rhijn M, Khairoun M, Lievers E, de Vries DK, Schaapherder AF, Wong SW, Zwaginga JJ, Duijs JM, van Zonneveld AJ, Hoogduijn MJ, Fibbe WE, de Fijter JW, van Kooten C, Rabelink TJ, Roelofs H.

Cytotherapy. 2013 Jun;15(6):663-72. doi: 10.1016/j.jcyt.2013.01.010. Epub 2013 Feb 16.

PMID:
23419679
12.

Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.

de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TJ, van Zonneveld AJ.

Eur Heart J. 2013 Nov;34(44):3451-7. doi: 10.1093/eurheartj/eht007. Epub 2013 Feb 4.

PMID:
23386708
13.

MicroRNA-155 functions as a negative regulator of RhoA signaling in TGF-β-induced endothelial to mesenchymal transition.

Bijkerk R, de Bruin RG, van Solingen C, Duijs JM, Kobayashi K, van der Veer EP, ten Dijke P, Rabelink TJ, Goumans MJ, van Zonneveld AJ.

Microrna. 2012;1(1):2-10.

PMID:
25048084
14.

Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia.

Loomans CJ, van Haperen R, Duijs JM, Verseyden C, de Crom R, Leenen PJ, Drexhage HA, de Boer HC, de Koning EJ, Rabelink TJ, Staal FJ, van Zonneveld AJ.

Mol Med. 2009 May-Jun;15(5-6):152-9. doi: 10.2119/molmed.2009.00032. Epub 2009 Mar 11.

15.

Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis.

van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ.

J Cell Mol Med. 2009 Aug;13(8A):1577-85. doi: 10.1111/j.1582-4934.2008.00613.x.

16.

Erythropoietin, progenitors, and repair.

Aydin Z, Duijs J, Bajema IM, van Zonneveld AJ, Rabelink TJ.

Kidney Int Suppl. 2007 Nov;(107):S16-20. Review.

17.

Activation of the lectin pathway in murine lupus nephritis.

Trouw LA, Seelen MA, Duijs JM, Wagner S, Loos M, Bajema IM, van Kooten C, Roos A, Daha MR.

Mol Immunol. 2005 Apr;42(6):731-40.

PMID:
15781117
18.

Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR.

J Clin Invest. 2004 Sep;114(5):679-88.

19.

Anti-C1q autoantibodies in murine lupus nephritis.

Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos A, van Kooten C, Daha MR.

Clin Exp Immunol. 2004 Jan;135(1):41-8.

20.

Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG.

Trouw LA, Duijs JM, van Kooten C, Daha MR.

Mol Immunol. 2003 Dec;40(9):595-602.

PMID:
14597162
21.

Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies.

Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR.

Clin Exp Immunol. 2003 Apr;132(1):32-9.

22.

Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B.

Vidarsson G, van Der Pol WL, van Den Elsen JM, Vilé H, Jansen M, Duijs J, Morton HC, Boel E, Daha MR, Corthésy B, van De Winkel JG.

J Immunol. 2001 May 15;166(10):6250-6.

Supplemental Content

Support Center